Ctt Pharmaceutical Holdings Stock Gross Profit
| CTTH Stock | USD 0.05 0 2.97% |
CTT Pharmaceutical Holdings fundamentals help investors to digest information that contributes to CTT Pharmaceutical's financial success or failures. It also enables traders to predict the movement of CTT Pink Sheet. The fundamental analysis module provides a way to measure CTT Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CTT Pharmaceutical pink sheet.
CTT |
CTT Pharmaceutical Holdings Company Gross Profit Analysis
CTT Pharmaceutical's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, CTT Pharmaceutical Holdings reported 0.0 of gross profit. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
CTT Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTT Pharmaceutical's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CTT Pharmaceutical could also be used in its relative valuation, which is a method of valuing CTT Pharmaceutical by comparing valuation metrics of similar companies.CTT Pharmaceutical is currently under evaluation in gross profit category among its peers.
CTT Fundamentals
| Return On Equity | -4.49 | |||
| Return On Asset | -1.54 | |||
| Current Valuation | 18.87 M | |||
| Shares Outstanding | 21.32 M | |||
| Price To Earning | (3.00) X | |||
| Price To Book | 10.64 X | |||
| Revenue | 40 K | |||
| Net Income | (1.38 M) | |||
| Cash And Equivalents | 32.12 K | |||
| Total Debt | 87.62 K | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 5.01 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (145.16 K) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.14 | |||
| Market Capitalization | 16.17 M | |||
| Total Asset | 186.54 K | |||
| Net Asset | 186.54 K |
About CTT Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTT Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTT Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTT Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CTT Pink Sheet
CTT Pharmaceutical financial ratios help investors to determine whether CTT Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CTT with respect to the benefits of owning CTT Pharmaceutical security.